Browse drugs

…n and improvement were 48.5% and 38.8%, respectively. Long-term natalizumab treatment significantly decreased ARR compared with short-term …

…-CD20 therapy (768 on rituximab and 509 on ocrelizumab) and 677 natalizumab. Natalizumab significantly reduced ARR compared with anti-CD20 …

…ower compared with those with high trough concentrations during natalizumab treatment. This emphasises the importance of personalised EID, …

…peutic lag and differences between ASCEND and SPECTRIMS trials, natalizumab, compared with interferon β-1a, reduces disability progression …

…etween placebo groups (HR 0.36, 95% CI 0.20 to 0.63, p=0.0004), natalizumab remained associated with a lower hazard of disability progressi…

…pse risk (1.35, 1.16 to 1.57) and RAW (1.77, 1.07 to 2.94) than ocrelizumab. Alemtuzumab was associated with higher ARR (0.18 vs 0.12, p<0.…

…o conduct a five-year budget impact analysis (BIA) comparing IV natalizumab biosimilar with the SC originator in a hospital setting, and a …

…vels with the Tyruko new JCV titre assay. In 2 (8.7%) patients, Tyruko was discontinued due to new radiological findings.Conclusion Fu…

…nfants, most were breastfed on natalizumab (n=125), followed by ocrelizumab (n=34), rituximab (n=11) and ofatumumab (n=10); three had multi…

…se modifying therapy influence CD19+ B-cell repopulation during ocrelizumab treatment. With further elucidation of the association between …

…n. It is noticed that two patients switched from ocrelizumab to ofatumumab: one due to infusion-related adverse effects and another for lo…

…allenges when pregnancy is planned. Anti-CD20 therapies such as ofatumumab are effective; however, their safety during pregnancy remains u…